PCCA Appoints Gus Bassani, PharmD, as CEO

HOUSTON, March 20, 2025 – PCCA, a leading FDA-registered supplier of active pharmaceutical ingredients, excipients and consulting for the compounding industry, today announced Gus Bassani, PharmD, will become chief executive officer of its U.S. business unit on April 1, elevating a company veteran with extensive scientific leadership.

Bassani has been with PCCA since 2002. Most recently, he served as its chief scientific officer, leading the company’s research and development, clinical services and formulation development teams. In addition, he has been highly active in business development for the company, as well as legislative, regulatory and public affairs efforts in the compounding pharmacy sector.

Former PCCA CEO David L. Sparks and former PCCA President Jim Smith will continue to serve PCCA in key full-time leadership roles. Sparks will become chairman of the board, and Smith will serve as executive advisor to the board of directors. Their decades of experience and insight will continue to provide leadership, strategy and governance across PCCA and its affiliated companies.

Smith, who has made significant contributions to PCCA during his 25-year tenure with the company, said that under Bassani, PCCA will maintain the company’s commitment to delivering exceptional support to the 3,000 community pharmacies and health systems it serves.

“Having the privilege to serve as PCCA’s president for 16 years is an honor I’ll always cherish,” Smith said. “Gus is a gifted leader who has been an integral part of PCCA’s innovation, growth and success. His deep understanding of our industry, coupled with his experience as a pharmacist and his groundbreaking approach to compounding pharmacy, makes him the ideal CEO to guide PCCA into the future.”

Bassani said PCCA will continue to press into the areas it has become known for: pioneering new developments; maintaining the robustness of its quality systems and supply chain; and empowering compounding pharmacies with high-quality products, clinical research and consultative services, ensuring they have the resources needed to deliver personalized care to their patients.

“I am honored to take on this new role, alongside our dynamic and talented team at PCCA,” Bassani said. “Service to pharmacies in community and hospital settings and the safety and care of the patients they serve will always be the cornerstone of our mission.”

Bassani said compounding pharmacists will play a key role in the advancement of personalized medicine, integrating innovations like pharmacogenomics, automation and cutting-edge formulation technologies to create precise therapies. He favors expanding research and strategic investments, including the development of new drug delivery technologies and formulations.

Before joining PCCA as a consultant pharmacist, Bassani was a formulation pharmacist in the pharmaceutical industry and worked in various pharmacy practice settings in Alaska, Iowa and Kansas. He also taught extemporaneous compounding principles at Drake University in Des Moines, where he earned his Doctor of Pharmacy degree.

He has served multiple terms on the United States Pharmacopeia (USP) Compounding Expert Committee. He is also a member of several professional organizations, including the Alliance for Pharmacy Compounding (APC), American Pharmacists Association (APhA) and National Community Pharmacists Association (NCPA).

ABOUT PCCA

PCCA supports the creation of personalized medicine and innovative products that make a difference in patients’ lives. As a complete resource for independent compounding pharmacies and health systems, PCCA provides high-quality products, education and support to more than 3,000 pharmacy members throughout the United States, Canada, Australia and other countries around the world. Incorporated in 1981 by a network of pharmacists, PCCA has supported pharmacy compounding for more than 40 years. Learn more at pccarx.com.

CONFIDENTIALITY NOTE: This e-mail, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of this transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. The contents of this e-mail do not necessarily represent the views or policies of PCCA or its employees.